| Sydney, Australia, 20 September 2019: Recce Pharmaceuticals Ltd (ASX: RCE) (Recce or the Company), developing a new class of synthetic antibiotics, is pleased to announce the Japan Patent Office (JPO) has Granted a second patent for wholly owned RECCE® antibiotics, including lead compound RECCE® 327, furthering marketing/manufacturing monopolies and expanding clinical indications. This second patent family, titled ‘Copolymer for use in a method of treatment of a parenteral infection’, contains 13 claims and relates to methods of manufacture, administration and application to treat a broad range of common human infections, providing Recce intellectual property protection to November 2035. Japan is the second largest pharmaceutical market in the world1 and reaffirms RECCE® antibiotics capability against Gram-positive and Gram-negative bacteria, including their superbug forms, with particular claim to efficacy against: Proteus spp, Serratia spp, Pseudomonas aeruginosa, Neisseria meningitidis, Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, coagulase-negative Staphylococcus spp, Streptococcus pyogenes, Streptococcus pneumoniae and Enterococcus spp. The listed bacteria can be life-threatening if contracted. Recce Pharmaceuticals Chairman Dr John Prendergast said: “We are very pleased to continue the expansion of Recce’s Worldwide Patent portfolio. The strength of our patent coverage is yet another step in the commercialization of RECCE antibiotics across multiple geographic regions.” (1) https://www.worldatlas.com/articles/countries-with-the-biggest-global-pharmaceutical-markets-in-the-world.html |
